Claims
- 1. A method for identifying a compound capable of treating a hematologic disorder, comprising assaying the ability of the compound to modulate 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 nucleic acid expression or 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 polypeptide activity, thereby identifying a compound capable of treating a hematologic disorder.
- 2. A method for identifying a compound capable of modulating hematopoeisis comprising:
a) contacting a cell which expresses 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 with a test compound; and b) assaying the ability of the test compound to modulate the expression of a 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 nucleic acid or the activity of a 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 polypeptide, thereby identifying a compound capable of modulating hematopoeisis.
- 3. A method for modulating hematopoeisis in a cell comprising contacting a cell with a 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator, thereby modulating hematopoeisis in the cell.
- 4. The method of claim 2, wherein the cell is a hematopoeitic cell.
- 5. The method of claim 3, wherein the 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is a small organic molecule, peptide, antibody or antisense nucleic acid molecule.
- 6. The method of claim 3, wherein the 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is capable of modulating 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 polypeptide activity.
- 7. The method of claim 6, wherein the 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is a small organic molecule, peptide, antibody or antisense nucleic acid molecule.
- 8. The method of claim 6, wherein the 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is capable of modulating 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 nucleic acid expression.
- 9. A method for treating a subject having a hematologic disorder characterized by aberrant 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 polypeptide activity or aberrant 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 nucleic acid expression comprising administering to the subject a 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator, thereby treating said subject having a hematologic disorder.
- 10. The method of claim 9, wherein said hematological disorder is selected from the group consisting of disorders resulting from bone marrow irradiation or chemotherapy treatments for cancer, Pernicious Anemia, Hemorrhagic Anemia, Hemolytic Anemia, Aplastic Anemia, Sickle Cell Anemia, Sideroblastic Anemia, Anemia associated with chronic infections such as Malaria, Trypanosomiasis, HIV, Hepatitis virus or other viruses, Myelophthisic Anemias caused by marrow deficiencies, renal failure resulting from Anemia, Anemia, Polycethemia, Infectious Mononucleosis (IM), Acute Non-Lymphocytic Leukemia (ANLL), Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Acute Myelomonocytic Leukemia (AMMoL), Polycethemia Vera, Lymphoma, Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia, Wilm's Tumor, Ewing's Sarcoma, Retinoblastoma, Hemophilia, disorders associated with an increased risk of Thrombosis, Herpes, Thalessemia, antibody-mediated disorders such as transfusion reactions and Erythroblastosis, mechanical trauma to red blood cells such as micro-angiopathic hemolytic anemias, Thrombotic Thrombocytopenic Purpura and disseminated intravascular coagulation, infections by parasites such as Plasmodium, chemical injuries from, e.g., lead poisoning, and Hypersplenism.
- 11. The method of claim 9, wherein said 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is administered in a pharmaceutically acceptable formulation.
- 12. The method of claim 9, wherein the 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is a small organic molecule, peptide, antibody or antisense nucleic acid molecule.
- 13. The method of claim 9, wherein the 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 modulator is capable of modulating 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 polypeptide activity.
Parent Case Info
[0001] This application claims priority to U.S. provisional application No. 60/347,949, filed Nov. 7, 2001, the entire contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60347949 |
Nov 2001 |
US |